🗣️ Albemarle Corporation, a well-established firm, exhibits strong dividend stability, maintaining consistency over the past 32 years. The company offers a moderate yield of 2.13%, with a diligent growth approach. Despite current challenges in profitability, its long-term dividend reliability boosts investor confidence.
Albemarle Corporation operates within the Chemicals sector and has admirably maintained steady dividends over an impressive span of 32 years, indicating robust dividend reliability and investor trust.
Metric | Details |
---|---|
Sector | Chemicals |
Dividend Yield | 2.13% |
Current Dividend Per Share | 2.65 USD |
Dividend History | 32 years |
Last Cut or Suspension | None |
Albemarle's dividend history stands out with 32 years of uninterrupted payments, which serves as a beacon of its stable financial management. Historical performance is a critical factor for income-focused investors.
Year | Dividend Per Share (USD) |
---|---|
2025 | 1.215 |
2024 | 1.610 |
2023 | 1.600 |
2022 | 1.580 |
2021 | 1.560 |
The firm’s dividend growth over 3 and 5 years suggests a conservative but consistent appreciation, essential for long-term dividend growth strategies.
Time | Growth |
---|---|
3 years | 1.06% |
5 years | 1.84% |
The average dividend growth is 1.84% over 5 years. This shows moderate but steady dividend growth.
Currently, Albemarle’s payout ratios are negative across EPS and FCF metrics, an indicator of potential operational reinvestments or temporary income challenges.
Key Figure | Ratio |
---|---|
EPS-based | -33.53% |
Free cash flow-based | -174.78% |
While these negative figures indicate reinvestment efforts or income fluctuations, they necessitate close monitoring to assess future dividend sustainability.
Evaluating the determinants of free cash flow yield and operating cash ratio reveals insights into Albemarle's operational liquidity and reinvestment efficiency.
Year | 2024 | 2023 | 2022 |
---|---|---|---|
Free Cash Flow Yield | -9.72% | -4.86% | 2.54% |
Earnings Yield | -11.66% | 9.28% | 10.59% |
CAPEX to Operating Cash Flow | 240.12% | 162.17% | 66.13% |
Stock-based Compensation to Revenue | 0.60% | 0.38% | 0.42% |
Free Cash Flow / Operating Cash Flow Ratio | -140.12% | -62.02% | 33.87% |
Notable fluctuations in cash flow yield reflect operational investments; however, positive shifts in operating cash flow ratio illustrate improvements towards capital efficiency.
Debt assessment metrics such as debt-to-equity and net debt to EBITDA ratios are paramount in deciphering financial health and leverage capacity.
Year | 2024 | 2023 | 2022 |
---|---|---|---|
Debt-to-Equity | 36.30% | 45.48% | 41.54% |
Debt-to-Assets | 21.77% | 23.43% | 21.46% |
Debt-to-Capital | 26.63% | 31.26% | 29.35% |
Net Debt to EBITDA | -2.40 | 4.28 | 0.64 |
Current Ratio | 0 | 0 | 0 |
Quick Ratio | 1.19 | 0.86 | 1.13 |
The leverage position indicates a controlled debt structure, though the net debt to EBITDA ratio in recent years suggests a potential risk in cash flow coverage.
Core profitability indicators such as return on assets and equity underscore Albemarle’s operational efficacy and profit margins' trajectory.
Year | 2024 | 2023 | 2022 |
---|---|---|---|
Return on Equity | -11.84% | 16.72% | 33.70% |
Return on Assets | -7.10% | 8.61% | 17.40% |
Margins: Net | -21.93% | 16.36% | 36.75% |
Margins: EBIT | -29.72% | 3.77% | 34.92% |
Margins: EBITDA | -18.77% | 8.24% | 39.03% |
Margins: Gross | 1.16% | 12.33% | 42.00% |
R&D to Revenue | 1.61% | 0.89% | 0.98% |
Profitability metrics illustrate volatility, yet show strong R&D investment commitment which can fuel future advances and market positioning.
Criteria | Score | |
---|---|---|
Dividend yield | 3 | |
Dividend Stability | 5 | |
Dividend growth | 2 | |
Payout ratio | 2 | |
Financial stability | 3 | |
Dividend continuity | 5 | |
Cashflow Coverage | 3 | |
Balance Sheet Quality | 3 |
Albemarle Corporation demonstrates strong dividend stability marked by an illustrious history of 32 consistent years. However, current fiscal metrics signal apprehension necessitating critical oversight. The enterprise's commitment to R&D and innovation posits long-term potential, yet prudence is advised amidst evident profit volatility. A hold recommendation is suitable under current forecasts, but prospective capital appreciations could prove opportunistic as operational efficiencies strengthen.